OBJECTIVES: The natural history of ulcerative colitis (UC) has been poorly described in
children. METHODS: In a geographically derived incidence cohort diagnosed from 1988 to …

BACKGROUND & AIMS: It is uncertain whether mucosal healing after the first course of
corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We …

Conventional therapies for ulcerative colitis and Crohn's disease (CD) include
aminosalicylates, corticosteroids, thiopurines, methotrexate, and anti–tumor necrosis factor …

It is important to have clear goals for treating inflammatory bowel disease in clinical practice
and in research. Conventional end points for trials in ulcerative colitis and Crohn's disease …

Most of the drugs used in the treatment of inflammatory bowel disease (IBD) become
systemically bioavailable and potentially bear strong adverse effects. Targeting the inflamed …

BACKGROUND & AIMS:: Many patients with inflammatory bowel disease receive
corticosteroids and 6-mercaptopurine/azathioprine during elective bowel surgery. We …

Importance Treatment of Crohn disease is rapidly evolving, with the induction of novel
biologic therapies and newer, often more intensive treatment approaches. Knowing how to …

Background & Aims: The clinical manifestations of Crohn's disease (CD) are diverse,
ranging from fibrostenosing small-bowel disease to colon-predominant inflammation. These …

Infliximab, the chimeric monoclonal immunoglobulin (Ig) G1 antibody to tumor necrosis
factor (TNF) has changed our therapy of Crohn's disease. Infliximab is indicated in refractory …

Objectives: Medical treatment options and strategies for Crohn's disease (CD) have
changed over the past decades. To assess its impact, we studied the evolution of the long …